Conditional HIF-1alpha expression produces a reversible cardiomyopathy. - Wikidata - awgldk - TriplyDB

Conditional HIF-1alpha expression produces a reversible cardiomyopathy.

Conditional HIF-1alpha expression produces a reversible cardiomyopathy.

http://www.wikidata.org/entity/Q33640248

about

HIF hydroxylase pathways in cardiovascular physiology and medicine Conditional HIF-1 induction produces multistage neovascularization with stage-specific sensitivity to VEGFR inhibitors and myeloid cell independence.High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND.Establishment of a novel murine model of ischemic cardiomyopathy with multiple diffuse coronary lesions.Up-regulation of glycolytic metabolism is required for HIF1α-driven bone formation HIF-1α in the heart: remodeling nucleotide metabolism.Redox signaling in cardiac myocytes.Cardiomyocyte-specific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting Depletion of PHD3 protects heart from ischemia/reperfusion injury by inhibiting cardiomyocyte apoptosis.Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF-β signaling.PHD2/3-dependent hydroxylation tunes cardiac response to β-adrenergic stress via phospholamban.Heart-Specific Knockout of the Mitochondrial Thioredoxin Reductase (Txnrd2) Induces Metabolic and Contractile Dysfunction in the Aging Myocardium.Dysregulated expression of microRNAs and mRNAs in myocardial infarction.Differential localisation of BPIFA1 (SPLUNC1) and BPIFB1 (LPLUNC1) in the nasal and oral cavities of mice.EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection.Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.HIF-1α in heart: protective mechanisms.Cardiac angiogenesis directed by stable Hypoxia Inducible Factor-1.Signaling hypoxia by hypoxia-inducible factor protein hydroxylases: a historical overview and future perspectives The von Hippel-Lindau Chuvash mutation in mice alters cardiac substrate and high-energy phosphate metabolism.PET imaging of cardiac hypoxia: opportunities and challenges.Ischemia-induced copper loss and suppression of angiogenesis in the pathogenesis of myocardial infarction.Emerging paradigms in cardiomyopathies associated with cancer therapies.Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.HIF-mediated innate immune responses: cell signaling and therapeutic implications.The association of depressed angiogenic factors with reduced capillary density in the Rhesus monkey model of myocardial ischemia.Conditional hypoxia inducible factor-1α induction in embryonic pulmonary epithelium impairs maturation and augments lymphangiogenesis.Hypoxia-inducible factor-1α in pulmonary arterial smooth muscle cells and hypoxia-induced pulmonary hypertension.William Kaelin, Peter Ratcliffe, and Gregg Semenza receive the 2016 Albert Lasker Basic Medical Research Award.Cardio-oncology: it takes two to translate.Unfavourable consequences of chronic cardiac HIF-1α stabilization.Endurance training prevents negative effects of the hypoxia mimetic dimethyloxalylglycine on cardiac and skeletal muscle function.The adenosine salvage pathway as an alternative to mitochondrial production of ATP in maturing mammalian oocytes.HIF1 mediates a switch in pyruvate kinase isoforms after myocardial infarction.HIF-1, Metabolism, and Diabetes in the Embryonic and Adult Heart

P2860

Q26862091-F5B645F9-5CCC-4A0A-B254-C7092FB99688 Q30468545-A7E8E2DA-48DC-4D0B-99D8-E7F5A4C74398 Q31037729-193D6857-30C3-455C-A857-C09023B99C60 Q31126526-4074AFBF-62F5-4E17-861E-423E712BBEDF Q33767756-0B873E06-4533-4B82-B9EF-760084B0F8A6 Q34462754-082DC913-6B13-4B6A-84E9-6B7BA2C5CEDB Q34629326-C4F45607-9F5D-4077-8E0F-2F7016E35686 Q34719547-1F9DB94D-53E3-4B6C-9C05-4ACC30076DDB Q35164593-0284A538-4102-40E8-B4D5-1CF3E492D0FF Q35219366-FCF11BB1-873B-4086-BFAC-EBEC01187EB7 Q35887239-A1BF5DF5-2DBC-4681-BCE4-4C67708BB156 Q36040250-EA313681-9882-4477-8487-1CBC554F5001 Q36168834-161F3EF4-7F6A-438F-BB6F-6D8446905DFE Q36420256-9B80AA85-37A2-4CAE-B00C-011CE5062DC1 Q36420962-D729565B-8E2A-4207-9D9E-61292FA4A3C9 Q36762987-98A0E5FF-61ED-4F74-A8BC-F7E6DE8DB655 Q36891574-553E618E-2A9F-4AF0-937F-6F598D25906B Q37142770-893BC8A9-F489-4F09-8470-F7456D2221C9 Q37153863-D37BCEB9-7BBB-4C6E-96DE-85D778283B1A Q37301035-E32B2A0B-1D65-4F7B-8881-7E0E8EFE096F Q37480834-D2C67060-903C-4710-B5A1-FE3254839993 Q37904019-192B5281-4D4B-47C1-B4B9-CB82A0A57E48 Q38014352-00C0BB17-2C10-4D9F-AE9D-0AD6556A84B7 Q38132645-4B2A2F93-D65F-4383-8001-FD61995C6FEE Q38237495-03CBA471-CCEE-4FDA-B202-0A9B023E497D Q38989126-96254FC1-30BA-4F68-960C-880853BF21EB Q40017141-9170B64F-F862-4BC1-8D3B-BB9DAD6ADEAE Q40550707-B63EDD73-F624-41D8-A909-BB6EFED47514 Q42372083-93796E38-8933-4ACC-9076-423196D432ED Q42373787-E96FA74D-CEDC-4220-B72B-E0F754A8B162 Q44228500-1F450B9A-D26A-4A43-964B-E0E3F2E4DB97 Q46246985-739B5D6A-9172-4A81-B668-EB3E04D0E11F Q48278750-1DDA164A-F2B1-42C0-BC2B-5A8D2E4D1767 Q48596972-6B028E8C-CC2E-46C1-B7FC-9A375EB42BD1 Q52590030-CD2E522E-2147-47FA-A78B-33D810E91E4A Q58777512-85DBD677-E926-457E-ADED-255851638793

P2860

Conditional HIF-1alpha expression produces a reversible cardiomyopathy.

http://www.wikidata.org/entity/Q33640248

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Conditional HIF-1alpha expression produces a reversible cardiomyopathy.

@ast

Conditional HIF-1alpha expression produces a reversible cardiomyopathy.

@en

type

label

Conditional HIF-1alpha expression produces a reversible cardiomyopathy.

@ast

Conditional HIF-1alpha expression produces a reversible cardiomyopathy.

@en

prefLabel

Conditional HIF-1alpha expression produces a reversible cardiomyopathy.

@ast

Conditional HIF-1alpha expression produces a reversible cardiomyopathy.

@en

P1433

Q33640248-9CF7BDB6-46BC-4E26-BED8-A15F9668E539

P1476

Q33640248-E7987540-26FD-462B-9E8C-7A91177BC0A6

P2093

Q33640248-108AC206-97EC-4226-9822-2453CCE3565F

Q33640248-2CACF415-0A92-4FE7-80C6-3A53C2050E2B

Q33640248-3735F79D-134F-49F1-A434-48FEEDC62473

Q33640248-4D3D76B3-BD88-4EE5-A2AA-42203172C5A0

Q33640248-638E2E51-35D9-43E2-A746-7672BCB93C6A

Q33640248-813E5D34-F4E3-43C4-841F-8D466A769CBC

Q33640248-94C9BF91-FDEA-40EC-8709-6CF35AFAA350

Q33640248-B6193AEC-1969-4AFA-A353-03A1ADC75699

Q33640248-B8C1066D-FEC2-4CF1-B785-058C3BE85FB2

Q33640248-FD0CD909-4702-4660-BF6D-5D77A1475E55

P2860

Q33640248-108F540C-1219-486B-AA32-679B816307D0

Q33640248-2455686D-3E2C-4026-B508-036F89B4661C

Q33640248-33C802F9-BF73-4BDC-99C8-E76AB5A509FB

Q33640248-365EEACB-A292-44D5-A45C-6C0223C86AB8

Q33640248-45B91BC9-4EA9-41E0-B36C-C36A7210D76D

Q33640248-567C9812-3F29-464D-B6A4-12AD0CEB2395

Q33640248-5D1A397E-9E7B-4391-A0D9-2198EFCB8B4E

Q33640248-622B1DFB-3DA2-4FE5-AC03-3EF818954DD1

Q33640248-676417E8-30B4-428C-9745-4D75FF46E531

Q33640248-6A112FE9-DB52-4B4C-BE18-A3805524E257

P304

Q33640248-A119ADD2-1139-4E9F-94F1-AC809E8BC6F1

P31

Q33640248-1F64FFA6-AC17-4C9F-B2E5-08B0E767A096

P356

Q33640248-7135DDDA-DA90-44F0-B09B-CE3F16AB700D

P407

Q33640248-B31DF01B-BEC4-453E-ACEB-F83FB8EA4106

P433

Q33640248-4A02FC0F-1AC0-4440-93D7-0491A5DC11BA

P478

Q33640248-C1EF93DA-9E5F-4B09-A03B-0516B4FCD32C

P577

Q33640248-30ED044D-68D9-4628-B291-0C74FE7FDB4F

P5875

Q33640248-6ACC2859-55B8-49F1-AFD4-5850694795CC

P698

Q33640248-21DBC05F-B8D2-46A3-8EAF-A9073B5E2FD4

P932

Q33640248-14832979-3913-463F-891A-FBA27E481328

P356

JOURNAL.PONE.0011693

P1433

P1476

Conditional HIF-1alpha expression produces a reversible cardiomyopathy.

@en

P2093

Chad B Walton

http://www.w3.org/2001/XMLSchema#string

David Sutcliffe

http://www.w3.org/2001/XMLSchema#string

Fred Kruse

http://www.w3.org/2001/XMLSchema#string

Jennifer Ecker

http://www.w3.org/2001/XMLSchema#string

Joel T Outten

http://www.w3.org/2001/XMLSchema#string

Keith A MacCannell

http://www.w3.org/2001/XMLSchema#string

Raffi Bekeredjian

http://www.w3.org/2001/XMLSchema#string

Ralph V Shohet

http://www.w3.org/2001/XMLSchema#string

Richard K Bruick

http://www.w3.org/2001/XMLSchema#string

Robert D Gerard

http://www.w3.org/2001/XMLSchema#string

P2860

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

A conserved family of prolyl-4-hydroxylases that modify HIF

Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling

Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL

FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex

Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex

P304

e11693

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0011693

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45288666

http://www.w3.org/2001/XMLSchema#string

P698

20657781

http://www.w3.org/2001/XMLSchema#string

P932

2908132

http://www.w3.org/2001/XMLSchema#string